Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

To the Filipino doctor's utter dissapointment, he did not receive any financial compensation for his milestone discovery.

Eli Lilly & Company to establish new global capability centre in Hyderabad, recruiting over 1,000 professionals for advanced ...

A new study questioned the clinical utility of an algorithm meant to predict opioid use disorder (OUD) risk based on 15 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Finbold has selected three interesting pharmaceutical stocks that could see significant moves to the upside in 2025.